RAD51D and ovarian cancer: c.270_271dupTA; p.(Lys91Ilefs*13) mutation carriers with high-grade ovarian cancer with metastasis also demonstrated a good response to PARPi for 15 months before the gain of secondary somatic RAD51D mutation [52].